_1568958365 1568958365 Editor editor.jddt@gmail.com UJPR Universal Journal of Pharmaceutical Research Univ J Pharm Res 2456-8058 04 11 2018 Kaijian Hou Chao Chen Xuhuang Wang Yuanyuan Guo Objective of present study was to analyze the effect of emodin on blood glucose and body weight in rats with type 1 diabetes. A total of 45 healthy SD rats were selected followed by being adaptively fed for one week and then from them 15 rats were randomly selected out as the control group and the remaining 30 healthy SD rats were given intraperitoneal injection of streptozotocin to establish diabetic model with the control group receiving intraperitoneal injection of citrate buffer solution of same doses; At the fifth day, the rats were fasted for 6h and appropriately fed with water. Then the tail blood was collected to measure the fasting blood glucose of rats and this step was repeated 15 days after the injection of streptozotocin. The diabetic rat model was established successfully when the blood glucose was detected to be no less than 16.9mmol/L; thirty diabetic model rats were randomly divided into diabetes group and emodin group with 15 cases in each group (n = 15); 15 days later, the rats in diabetes group and control group were treated with intragastric administration of PBS, 5ml/kg, and the rats in emodin group were given intragastric administration of emodin suspension (8g/L), 5ml/kg. The changes of fasting blood glucose and body weight were observed and compared in three groups from the time point of before model establishment to fifth and fifteenth days after successful establishment of model. There was no significant difference among three groups in fasting blood glucose and body weight at the initial stage of establishing model; In diabetes group and emodin group, the   rat’s body weight in T2 was significantly lower than that in T1 with the body weight decreasing more significantly in diabetes group (P<0.05), while the blood glucose in T2 was significantly higher than that in T1 with the blood glucose increasing more significantly in diabetes group (P<0.05). Emodin can relieve hyperglycemia in type I diabetic rats but has little influence on body weight. 07 01 2017 10.22270/ujpr.v2i4.R3 http://ujpr.org/index.php/journal/article/view/63 http://ujpr.org/index.php/journal/article/download/63/47 http://ujpr.org/index.php/journal/article/download/63/234 http://ujpr.org/index.php/journal/article/download/63/47 http://ujpr.org/index.php/journal/article/download/63/234